Scientific Director
Moderna TX
Christopher Rowbottom is a Scientific Director of Drug Metabolism and Pharmacokinetics (DMPK) at Moderna TX. With a Bachelor of Science degree from Michigan State University, Christopher has amassed over 18 years of experience in the pharmaceutical industry.
In his current role at Moderna, Christopher serves as a DMPK project representative, contributing to a range of preclinical and clinical programs in a range of therapeutic areas including infectious diseases, immuno-oncology, and rare diseases. Prior to joining Moderna, he spent 5 years at Biogen and 10 years at Eisai, where he played a pivotal role in small molecule drug discovery, with a focus on in vitro drug-drug interactions (DDI) involving CYP P450 enzymes and drug transporters.
At the conference, Christopher will be sharing his expertise on the pharmacokinetics of lipid nanoparticles, offering valuable insights into this cutting-edge area of research
Disclosure information not submitted.
Symposium: Advancing Vaccine Development: Utilizing the Power of Model-Based Approaches 2
Wednesday, October 23, 2024
9:00 AM – 10:30 AM MT
Wednesday, October 23, 2024
3:15 PM – 3:30 PM MT